Molecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translation - Report - MDSpire
Advertisement
Molecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translation
Clinical Report: Molecular Insights and Targeted Strategies for Reducing Embolic Risk in Cardiac Myxoma
Overview
This review discusses the molecular mechanisms underlying embolic risk in cardiac myxoma (CM) and highlights the role of tumor cell heterogeneity and the immunosuppressive microenvironment in driving embolic events.
Background
Cardiac myxoma is the most common primary cardiac tumor, with embolic complications occurring in 10%–25% of patients. Traditional risk assessments have focused on morphological features, which do not fully account for the variability in embolic events among patients. Recent advances in molecular profiling have begun to elucidate the biological mechanisms contributing to embolism in CM.
Data Highlights
No numerical data provided in the article.
Key Findings
Embolism in cardiac myxoma is driven by tumor cell heterogeneity and an immunosuppressive microenvironment.
A specific PLAT-high tumor subpopulation is associated with impaired cell adhesion and increased embolic risk.
Macrophage polarization towards an M2 phenotype contributes to tumor survival and friability.
Current clinical models for embolism prediction lack integration of molecular insights.
Targeted therapies, including phosphodiesterase inhibitors, may mitigate embolic risk.
Clinical Implications
Integrating molecular insights into clinical risk stratification may enhance the prediction of embolic events in cardiac myxoma patients.
Conclusion
This review discusses the understanding of embolic risk in cardiac myxoma and outlines potential strategies for clinical application based on molecular findings.
